{"title": "         ,       ", "author": "D V Maltsev; S K Yevtushenko", "url": null, "hostname": null, "description": "Background. Previously, the effectiveness of intravenous immunoglobulin therapy has been repeatedly reported in some children with autism spectrum disorders, without specifying selection criteria of potential responders to immunotherapy. Objective: to evaluate high-dose immunoglobulin therapy efficacy and safety in children with autism spectrum disorders and genetic deficiency of folate cycle.Materials and methods. The study group consisted of 78 children aged 2 to 10 years, who have been on intravenous immunoglobulin at a dose of 2 g/kg/month for 6 months. The control group included children of similar age and gender, who received only non-drug rehabilitation support. Nucleotide substitutions MTHFR677 C > T, MTHFR1298 A > C, MTRR A/G and MTR A/G in various combinations were detected by the polymerase chain reaction. The dynamics of psychiatric symptoms were assessed using the Aberrant Behavior Checklist scale.Results and discussion. The complete elimination of the phenotype of autism spectrum disorders was achieved in 21 patients, as well as marked improvement in other 33 children of the study group (p < 0.05; Z < Z0.05). In parallel, we have noted a positive dynamics of other clinical manifestations of folate cycle deficiency phenotype: PANDAS (in 19 out of 21), epileptic (in 29 out of 36) and gastrointestinal (in 49 out of 68 children) syndromes (p < 0.05; Z < Z0.05). There was no positive dynamics of the pyramidal tract lesion symptoms (p > 0.05; Z > Z0.05). A decrease in the total viral load and an increase in the number of natural killer cells in the blood (p < 0.05; Z < Z0.05) were marked. Almost complete elimination of leukoencephalopathy symptoms in the study group was observed in 29 patients, and a positive dynamics \u2014 in 24 cases (p < 0.05; Z < Z0.05). Conclusions. Intravenous immunoglobulin has a complex positive impact on the manifestations of a genetic deficiency of folate cycle, including autism spectrum disorders, extrapyramidal disturbances, bowel syndrome, epileptiform brain activity, immune deficiency, and leukoencephalopathy.", "sitename": "INTERNATIONAL NEUROLOGICAL JOURNAL", "date": "2022-01-26", "cleaned_text": "in Children with Autism Spectrum Disorders Associated with Genetic Deficiency of Folate Cycle Enzymes DOI: [https://doi.org/10.22141/2224-0713.2.80.2016.74004](https://doi.org/10.22141/2224-0713.2.80.2016.74004) Keywords:folate cycle, intravenous immunoglobulin, autism spectrum disorders Abstract Background. Previously, the effectiveness of intravenous immunoglobulin therapy has been repeatedly reported in some children with autism spectrum disorders, without specifying selection criteria of potential responders to immunotherapy. Objective: to evaluate high-dose immunoglobulin therapy efficacy and safety in children with autism spectrum disorders and genetic deficiency of folate cycle. Materials and methods. The study group consisted of 78 children aged 2 to 10 years, who have been on intravenous immunoglobulin at a dose of 2 g/kg/month for 6 months. The control group included children of similar age and gender, who received only non-drug rehabilitation support. Nucleotide substitutions MTHFR677 C > T, MTHFR1298 A > C, MTRR A/G and MTR A/G in various combinations were detected by the polymerase chain reaction. The dynamics of psychiatric symptoms were assessed using the Aberrant Behavior Checklist scale. Results and discussion. The complete elimination of the phenotype of autism spectrum disorders was achieved in 21 patients, as well as marked improvement in other 33 children of the study group (p < 0.05; Z < Z0.05). In parallel, we have noted a positive dynamics of other clinical manifestations of folate cycle deficiency phenotype: PANDAS (in 19 out of 21), epileptic (in 29 out of 36) and gastrointestinal (in 49 out of 68 children) syndromes (p < 0.05; Z < Z0.05). There was no positive dynamics of the pyramidal tract lesion symptoms (p > 0.05; Z > Z0.05). A decrease in the total viral load and an increase in the number of natural killer cells in the blood (p < 0.05; Z < Z0.05) were marked. Almost complete elimination of leukoencephalopathy symptoms in the study group was observed in 29 patients, and a positive dynamics \u2014 in 24 cases (p < 0.05; Z < Z0.05). Conclusions. Intravenous immunoglobulin has a complex positive impact on the manifestations of a genetic deficiency of folate cycle, including autism spectrum disorders, extrapyramidal disturbances, bowel syndrome, epileptiform brain activity, immune deficiency, and leukoencephalopathy. Downloads References .., Singh N.N., Stewart A.W., Field C.J. Psychometric characteristics of the aberrant behavior checklist // Am. J. Ment. Def. \u2014 1985. \u2014 Vol. 99. \u2014 P. 492-502. Baris S., Ercan H., Cagan H.H. Efficacy of intravenous immunoglobulin treatment in children. with common variable immunodeficiency // Immunol. \u2014 2011. \u2014 Vol. 21 (7). \u2014 P. 514-521. Billiau An.D., Witters epilepsy: on seizure activity and cerebrospinal fluid cytokine profile // Epilepsia. \u2014 2007. \u2014 Vol. 48. \u2014 P. 1739-1749. Binstock T. Intra-monocyte pathogens delineate autism subgroups // Med. Hypotheses. \u2014 2001. \u2014 Vol. 56 (4). \u2014 P. 523-531. Boris M., Goldblatt A., Edelson S.M., Edelson PA-C. Improvement in children with autism treated with intravenous gamma globulin // J. Nutr. Environ. Medicine. \u2014 2006. \u2014 Vol. 15 (4). \u2014 P. 1-8. Bradstreet J., Singh V.K., El-Dahr J. High dose intravenous immunoglobulin improves symptoms in children with autism // The international symposium on autism. \u2014 Dec. 28. 1999. \u2014 Atnhem, Netherlands. Buchwald B., Ahangari R., Weishaupt A., Toyka K.V. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barr\u00e9 syndrome // Annals of Neurology. \u2014 2002. \u2014 Vol. 51. \u2014 P. 673-680. Cabanlit M., Wills S., Goines P. et al. Brain-specific autoantibodies in the plasma of subjects with autistic spectrum disorder // Ann. N.Y. Acad. Sci. \u2014 2007. \u2014 Vol. 107. \u2014 P. 92-103. Chez G.M., Guido-Estrada N. Immune therapy in autism: historical experience and future directions with immunomodulatory therapy // Neurotherapeutists. \u2014 2010. \u2014 Vol. 7. \u2014 P. 293-301. Ciric B., Van Keulen V., Paz Soldan M. et al. Antibody-mediated remyelination operates through mechanism independent of immunomodulation // J. Neuroimmunology. \u2014 2004. \u2014 Vol. 146. \u2014 P. 153-161. Cowan J., Cameron D.W., Knoll G., Tay J. Protocol for updating a systematic review of randomised controlled trials on the prophylactic use of intravenous immunoglobulin for patients undergoing haematopoietic stem cell transplantation // BMJ Open. \u2014 2015. \u2014 Vol. 5 (8). \u2014 e008316. L.A., Matevia D status, anti-D immune globulin exposure during pregnancy, and risk of autism. spectrumdisorders // Am. J. Obstet. Gynecol. \u2014 2008. \u2014 Vo1. 99 (3). \u2014 P. 234. DelGiudice-Asch G., Simon L., Schmeidler J. Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism // J. Autism Dev. Disord. \u2014 1999. \u2014 Vol. 29 (2). \u2014 P. 157-160. Donati D., Akhyani N., Fogdell-Hahn A. et al. Detection of human herpesvirus6 in mesial temporal lobe epilepsy surgical brain resections // Neurology. \u2014 2003. \u2014 Vol. 61 (10). \u2014 P. 1405-1411. Engman M.L., Sundin M., Miniscalco C. Prenatal acquired cytomegalovirus infection should be considered in children with autism // Acta Paediatr. \u2014 2015. \u2014 Vol. 104 (8). \u2014 P. 792-795. Finberg R.W., Newburger J.W., Mikati M.A. et al. Effect of high doses of intravenously administered immune globulin on natural killer cell activity in peripheral blood // J. Pediatr. \u2014 1992. \u2014 Vol. 120 (3). \u2014 P. 376-380. Frye R.E. Metabolic and mitochondrial disorders associated with epilepsy in children with autism spectrum disorder // Epilepsy Behav. \u2014 2015. \u2014 Vol. 47. \u2014 P. 147-157. Ghaziuddin M., Al-Khouri I., Ghaziuddin N. Autistic symptoms following herpes encephalitis // Eur. Child. Adolesc. Psychiatry. \u2014 2002. \u2014 Vol. 11 (3). \u2014 P. 142-146. Gupta S. Treatment of children with autism with intravenous immunoglobulin // J. Child. Neurol. \u2014 1999. \u2014 Vol. 14 (3). \u2014 P. 203-205. Handen B.L., Melmed R.D., Hansen R.L. trial of oral human immunoglobulin for gastrointestinal dysfunction in children with autistic disorder // J. Autism. Dev. Disord. \u2014 2009. \u2014 Vol. 39 (5). \u2014 P. 796-805. Heuer L., Ashwood P., Schauer J. et al. Reduced Levels of Immunoglobulin in Children With Autism Correlates With Behavioral Symptoms // Autism. Res. \u2014 2008. \u2014 Vol. 1 (5). \u2014 P. 275-283. Hiroshi H., Seiji K., Toshihiro K., Nobuo K. An adult case suspected of recurrent measles encephalitis with psychiatric symptoms // Seishin Shinkeigaku Zasshi. \u2014 2003. \u2014 Vol. 105 (10). \u2014 P. 1239-1246. Jyonouchi H., Geng L., Streck D.L., Toruner G.A. Immunological characterization and transcription profiling of peripheral blood (PB) monocytes in children with autism spectrum disorders (ASD) and specific polysaccharide antibody deficiency (SPAD): case study // J. Neuroinflammation. \u2014 2012. \u2014 Vol. 9. \u2014 P. 4. Kamei A., Ichinohe S., Onuma R. et al. Acute disseminated demyelination due to primary human herpesvirus6 infection // Eur. J. Pediatr. \u2014 1997. \u2014 Vol. 156 (9). \u2014 P. 709-712. Kooij S.J., Bejerot S., Blackwell A. et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD // BMC Psychiatry. \u2014 2010. \u2014 Vol. 10. \u2014 P. 67. Marques F., Brito M.J., Conde M. Autism spectrum disorder secondary to enterovirus encephalitis // J. Child Neurol. \u2014 2014. \u2014 Vol. 29 (5). \u2014 P. 708-714. Monge-Galindo L., P\u00e9rez-Delgado R., L\u00f3pez-Pis\u00f3n J. Mesial temporal sclerosis in paediatrics: its clinical spectrum. Our experience gained over a 19-year period // Rev. Neurol. \u2014 2010. \u2014 Vol. 50 (6). \u2014 P. 341-348. Mostafa G.A., Al-Ayadhi L.Y. auto-antibodies in autistic children: relation to the disease severity // J. Neuroinflammation. \u2014 2011. \u2014 Vol. 25. \u2014 P. 8-39. Nicolson G.L., Gan R., human herpes virus6 coinfections in the blood of patients with autistic spectrum disorders // J. Neurosci Res. \u2014 2007. \u2014 Vol. 85 (5). \u2014 P. 1143-1148. Niederhofer H., Staffen W., Mair A. Immunoglobulins as an alternative strategy of psychopharmacological treatment of children with autistic disorder // Neuropsychopharmacology. \u2014 2003. \u2014 Vol. 28 (5). \u2014 P. 1014-1015. Perlmutter S.J., Leitman S.F., Garvey M.A. exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood // Lancet. \u2014 1999. \u2014 Vol. 354 (9185). \u2014 P. 1153-1158. Pinillos-Pis\u00f3n R., Llorente-Cereza M.T., L\u00f3pez-Pis\u00f3n J. infection by cytomegalovirus. A review of our 18 years' experience of diagnoses // Rev. Neurol. \u2014 2009. \u2014 Vol. 48 (7). \u2014 P. 349-353. Plebani A., Duse IgG subclass levels in intractable childhood epilepsy // Monogr. Allergy. \u2014 1988. \u2014 Vol. 23. \u2014 P. 204-215. Plioplys A.V. Intravenous immunoglobulin treatment of children with autism // J. Child. Neurol. \u2014 1998. \u2014 Vol. 13 (2). \u2014 P. 79-82. Price C.S., Thompson W.W., Goodson B. Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism // Pediatrics. \u2014 2010. \u2014 Vol. 126 (4). \u2014 P. 656-664 Puangpetch A., Suwannarat P., Chamnanphol M. et al. Significant Association of HLA-B Alleles and Genotypes in Thai Children with Autism Spectrum Disorders: A Case-Control Study // Dis. Markers. \u2014 2015. \u2014 Vol. 2015. \u2014 P. 724935. Reinert P., Moulias R., Goust J.M. Demonstration of cellular immunity deficiency limited to measles virus in 20 cases of subacute sclerosing leukoencephalitis // Arch. Fr. Pediatr. \u2014 1972. \u2014 (6). \u2014 P. 655-665. Ruiz J.E., Kwak J.Y., Baum L. et al. Intravenous immunoglobulin inhibits natural killer cell activity in vivo in women with recurrent spontaneous abortion // Am. J. Reprod. Immunol. \u2014 1996. \u2014 Vol. 35 (4). \u2014 P. 370-37. Russo A.J., Krigsman A., Jepson B., Wakefield A. Low serum myeloperoxidase in autistic children with gastrointestinal disease // Clinical and Experimental Gastroenterology. \u2014 2009. \u2014 Vol. 2. \u2014 P. 85-94. Santaella M.L., Varela Y., Linares N., Disdier O.M. Prevalence of autism spectrum disorders in relatives of patients with selective immunoglobulin A deficiency // P.R. Health. Sci J. \u2014 2008. \u2014 Vol. 27 (3). \u2014 P. 204-208. Schneider C.K., Melmed R.D., Barstow L.E. et al. immunoglobulin children with autism and gastrointestinal dysfunction: a prospective, open-label study // J. Autism. Dev. Disord. \u2014 2006. \u2014 Vol. 36 (8). \u2014 P. 1053-1064. Singh V.K., Lin S.X., Newell E., Nelson C. Abnormal measles-mumps-rubella antibodies and CNS autoimmunity in children with autism // J. Biomed. Sci. \u2014 2002. \u2014 Vol. 9 (4). \u2014 P. 359-364. Singh V.K., Warren R.P., Odell J.D. et al. Antibodies to myelin basic protein in children with autistic behavior // Brain. Behav. Immun. \u2014 1993. \u2014 Vol. 7 (1). \u2014 P. 97-103. Singh V.K., Lin S.X., Yang V.C. Serological association of measles virus and human with brain autoantibodies in autism // Clin. Immunol. Immunopathol. \u2014 1998. \u2014 Vol. 89 (1). \u2014 105-108. Strunk T., polymorphism // Med. Pediatr. Oncol. \u2014 2003. \u2014 Vol. 40 (1). \u2014 P. 48-50. Torrente F., Ashwood P., Day R. et al. Small intestinal enteropathy with epithelial IgG and complement deposition in children with regressive autism // Mol. Psychiatry. \u2014 2002. \u2014 Vol. 7 (4). \u2014 P. 375-382. Warren R.P., Odell J.D., Warren W.L. et al. Brief report: immunoglobulin A deficiency in a subset of autistic subjects // J. Autism. Dev. Disord. \u2014 1997. \u2014 Vol. 27 (2). \u2014 P. 187-192. Wasilewska J., Kaczmarski M., Stasiak-Barmuta A. et al. Low serum IgA and increased expression of CD23 on B lymphocytes in peripheral blood in children with regressive autism aged 3-6 years old // Arch. Med. Sci. \u2014 2012. \u2014 Vol. 8 (2). \u2014 P. 324-331. Wynn J.L., Seed P.C., Cotten C.M. Does IVIg administration yield improved immune function in very premature neonates? // J. Perinatol. \u2014 2010. \u2014 Vol. 30 (10). \u2014 P. 635-642. Downloads Published How to Cite Issue Section License Copyright (c) 2016 D.V. Maltsev, S.K. Yevtushenko This work is "}